Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Microsponge Drug Delivery Systems: Advancing Methotrexate Delivery for Rheumatoid Arthritis Management

View through CrossRef
An estimated 23 million individuals worldwide suffer with rheumatoid arthritis, a debilitating inflammatory illness with a prevalence incidence of 0.5–1%. This chronic illness mostly affects synovial joints, causing inflammation, joint degeneration, and bone erosion. Patients suffer from a very low quality of life, and the condition has a significant socioeconomic impact. The pathophysiology of RA is caused by a complicated interaction between genetic and environmental variables that disrupt the control of the immune system. TNF-α, IL-6, and IL-1β are important inflammatory mediators that cause bone resorption and joint degeneration as the illness progresses. Microsponge drug delivery systems have been developed as a promising strategy to improve the therapeutic efficacy of methotrexate, which is a cornerstone in RA treatment. These systems offer controlled release, improved bioavailability, and targeted delivery to inflamed joints while minimizing systemic toxicity. Microsponge drug delivery systems can be formulated as topical gels, creams, patches, or injectable hydrogels, which allows for a variety of administration routes. Microsponge drug delivery systems are known for offering benefits of delivering methotrexate drugs by sustaining its release, providing reduced dosing, stability in the drug itself, and causing less side effect. Some challenges of microsponge drug delivery systems include a complicated manufacturing process, scalability issues, and regulatory problems that hamper its application in the clinic. In order to prove the safety and effectiveness of microsponge drug delivery systems, future research will concentrate on refining their composition, developing scalable production methods, and conducting extensive clinical studies. Innovation will keep developing, and by enhancing patient adherence, therapeutic results, and the quality of life for patients suffering from rheumatoid arthritis, microsponge drug delivery systems have the potential to completely transform the way this chronic illness is treated.
Title: Microsponge Drug Delivery Systems: Advancing Methotrexate Delivery for Rheumatoid Arthritis Management
Description:
An estimated 23 million individuals worldwide suffer with rheumatoid arthritis, a debilitating inflammatory illness with a prevalence incidence of 0.
5–1%.
This chronic illness mostly affects synovial joints, causing inflammation, joint degeneration, and bone erosion.
Patients suffer from a very low quality of life, and the condition has a significant socioeconomic impact.
The pathophysiology of RA is caused by a complicated interaction between genetic and environmental variables that disrupt the control of the immune system.
TNF-α, IL-6, and IL-1β are important inflammatory mediators that cause bone resorption and joint degeneration as the illness progresses.
Microsponge drug delivery systems have been developed as a promising strategy to improve the therapeutic efficacy of methotrexate, which is a cornerstone in RA treatment.
These systems offer controlled release, improved bioavailability, and targeted delivery to inflamed joints while minimizing systemic toxicity.
Microsponge drug delivery systems can be formulated as topical gels, creams, patches, or injectable hydrogels, which allows for a variety of administration routes.
Microsponge drug delivery systems are known for offering benefits of delivering methotrexate drugs by sustaining its release, providing reduced dosing, stability in the drug itself, and causing less side effect.
Some challenges of microsponge drug delivery systems include a complicated manufacturing process, scalability issues, and regulatory problems that hamper its application in the clinic.
In order to prove the safety and effectiveness of microsponge drug delivery systems, future research will concentrate on refining their composition, developing scalable production methods, and conducting extensive clinical studies.
Innovation will keep developing, and by enhancing patient adherence, therapeutic results, and the quality of life for patients suffering from rheumatoid arthritis, microsponge drug delivery systems have the potential to completely transform the way this chronic illness is treated.

Related Results

THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
CYTOKINES IN SLE: LESSONS FROM EXPERIMENTAL MODELS AND MAN, Michael J Elliott*., Peter Charles, Ravinder N MainiTHE FAS GENE IN HUMAN LUPUS: THE EXPRESSION OF VARIANT TRANSCRIPTS.,...
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
The followina are abstracts of papers presented at the 35th Annual Scientific Meeting of the Australian Rheumatology Association, held in Perth, Western Australia, 1–4 December. 19...
Hubungan Rheumatoid Arthritis dengan Kejadian Insomnia pada Usia Lanjut
Hubungan Rheumatoid Arthritis dengan Kejadian Insomnia pada Usia Lanjut
One of the health problems often experienced by the elderly is rheumatoid arthritis. Joint disorders experienced by people with rheumatoid arthritis will have an impact on physical...
Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis
Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis
BackgroundIt remains unclear whether active pulmonary tuberculosis risk is still high in rheumatoid arthritis patients in settings where tuberculosis infection screening is perform...
Diagnosis of Felty Syndrome prior to onset of Rheumatoid Arthritis
Diagnosis of Felty Syndrome prior to onset of Rheumatoid Arthritis
Abstract Felty Syndrome is the triad of rheumatoid arthritis, neutropenia, and splenomegaly. The cause of Felty Syndrome is unknown, but neutropenia is thought to be due to...
Therapeutic Effect of Berberine Versus Methotrexate on Histopathology in a Rat Model of Pristane-Induced Arthritis
Therapeutic Effect of Berberine Versus Methotrexate on Histopathology in a Rat Model of Pristane-Induced Arthritis
Introduction: Treatment options for rheumatoid arthritis have potentially fatal adverse effects and failure to achieve complete cure. Alternative medicines are, therefore, being re...
Formulation, Development and Evaluation of Microsponge Based Gel of Crisaborole
Formulation, Development and Evaluation of Microsponge Based Gel of Crisaborole
The objective of present research work was to formulate microsponge gel of crisaborole drug for the treatment of atopic dermatitis. By using 32 full factorial design optimization o...

Back to Top